Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...

Alector (NASDAQ:ALEC) shares extended post-market losses to drop ~50% in the premarket on Wednesday after the ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...

Alector said it will cut its workforce nearly in half after discontinuing trials for latozinemab, an investigational treatment for dementia. The biopharmaceutical company said it would reduce its ...

Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while ...

Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...